News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theravalues Release: A Clinical Study Shows the Theracurmin®'s Safety and Potential Role in Improving Quality of Life (QOL) of Pancreatic Cancer Patients


5/10/2013 10:15:33 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TOKYO--(BUSINESS WIRE)--Theravalues, Japan-based biotechnology innovator, announced today that a recent phase I clinical trial on the pancreatic cancer patients using Theracurmin®, an enhanced form of curcumin that allows for greater absorption, has no adverse effect for both of dose levels (200mg/day and 400mg/day) on cancer patients. The study also discovered that the Theracurmin® dosage helped improve a whole range of Quality of Life (QOL) scores of the patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES